Growth Hormone / side effects and safety / Last reviewed 2026-06-02

GHRP-2 Side Effects: Safety Signals and Warnings

GHRP-2 safety concerns are compound-specific. The main listed side effects are Mild appetite increase, Transient cortisol elevation, and Mild prolactin increase. The main warning signals are Not FDA approved (approved in Japan for diagnostic use only), Should not be used in patients with active malignancy, and Tachyphylaxis possible with continuous use.

Read the full GHRP-2 guide Browse answer pages

Direct Answer

Evidence for GHRP-2 is too preliminary to support a research protocol with confidence. Like GHRP-6, it raises cortisol and prolactin alongside GH, limiting its practical utility. It is more potent than GHRP-6 but that potency comes with the same hormonal side effects. Of the Growth Hormone secretagogues in this library, ipamorelin or MK-677 are better-evidenced starting points.

Evidence grade
Level C
Research status
Preclinical
Category
Growth Hormone
Best for
GHRP receptor pharmacology, second-generation GHRP mechanistic research

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Approved in Japan as a diagnostic agent (GHRP Kaken). Not approved by FDA. Available as research chemical elsewhere. Banned by WADA.

Evidence Snapshot

Evidence gradeLevel C
Research statusPreclinical
Best supported outcomesGrowth Hormone Release (Level B), Appetite Stimulation (Level C), and Cortisol and Prolactin Effects (Level C)
Primary citation count2
Last reviewed2026-06-02

Related Guides

How to Cite This Page

ExaminePeptides. "GHRP-2 Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/ghrp-2-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.